News and Trends 24 Feb 2025 Over $3 billion in a month: Why is Eli Lilly starting 2025 on a buying spree? …Lilly kicked off the year collaborating with British startup Alchemab Therapeutics to discover and develop five antibodies with the help of the latter’s antibody discovery platform to treat amyotrophic lateral… February 24, 2025 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 13 Sep 2017 A Swedish-Spanish Team Takes on a New Immuno-Oncology Target …cells and can promote the survival, expansion and activity of these immune cells specialized in fighting cancer. Alligator Bioscience already has two antibody candidates in its pipeline that target… September 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 8 Jan 2018 Meet the Swiss CEO Pulling Out All the Stops Against Alzheimer’s Disease …exactly because of a lack of diagnostic. When we entered the field, it was clear to us that we needed a safe and pathological protein-specific antibody for efficacious treatment. Aβ… January 8, 2018 - 8 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jun 2022 Elektrofi raises $40M to develop drug formulation and delivery pipeline …antibody treatments for COVID-19 and pandemic preparation. Elektrofi said it aims to provide an alternative to current delivery methods for antibody treatments, which require intravenous administration in a healthcare setting…. June 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Dec 2016 The Largest Deals, Fundraising and Exits of 2016 in European Biotech …€96M round. The Swiss company develops antibody-drug conjugates (ADCs) for oncology applications, a technology challenging CAR-T immunotherapy. Its ambitious plan for the funds is to advance 6 clinical programs focusing… December 26, 2016 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2021 The Top European Biotech Investment Rounds in October …in September, there was only one modest IPO in October. The French firm Acticor Biotech raised €15.5M when listing on Euronext Growth Paris to fund the development of its antibody… November 2, 2021 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 9 Apr 2024 Eight biotech companies you should know about in Austria …most advanced is the chronic inflammation candidate ON104, which is a monoclonal antibody that helps override the immunosuppressive effects of glucocorticoids and neutralize the effects of oxMIF. ON104 is in… April 9, 2024 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jul 2022 Agomab bags $114 million in thriving regenerative medicine sector …led by Redmile Group in March 2021. The fresh funding is intended to advance the clinical development of Agomab’s pipeline. The firm is developing small molecules and monoclonal antibody drugs… July 14, 2022 - 3 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 26 Aug 2022 Cholesterol targeting antibodies produced by Bio-Rad Laboratories …and anti-drug antibody (ADA) assays for evolocumab and its biosimilars. Bio-Rad says that evolocumab is a monoclonal antibody used for the treatment of hyperlipidemia, or elevated levels of cholesterol and… August 26, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2023 Endometrial cancer drug receives breakthrough therapy designation in China …sintilimab (a PD-1 antibody) for the treatment of patients with advanced endometrial cancer with pMMR tumors that have failed at least one line of platinum-based therapy. A study for potential… July 20, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2023 CatalYm shows importance of GDF-15 in tumor immunotherapy resistance …further highlight the therapeutic significance of its proprietary anti-GDF-15 antibody candidate, visugromab, currently in advanced phase 2 clinical studies. The foundational research, which was performed with founder Jörg Wischhusen and… July 20, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 28 Nov 2022 Lyvgen and Bristol Myers Squibb commitment to transform cancer care …for patients who cannot benefit from existing therapy worldwide.” Lyvgen clinical collaboration LVGN7409, a recombinant monoclonal antibody that targets CD40 for activation optimally in tumor microenvironment, which is a member… November 28, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email